Weight Watchers Introduces Foundayo GLP-1 Medication Through Partnership With Eli Lilly

Weight Watchers has announced the launch of Eli Lilly and Company’s new oral GLP-1 medication, Foundayo®, which will be available through LillyDirect. The collaboration introduces a prescription-based option for individuals seeking weight management solutions. This marks an expansion in Weight Watchers’ offerings, incorporating pharmaceutical interventions alongside its established lifestyle programs.

Foundayo® is part of the GLP-1 receptor agonist class of medications, which are designed to assist with weight loss by regulating appetite and glucose levels. The availability of this medication through LillyDirect provides a streamlined process for patients to access prescriptions directly from Eli Lilly. This initiative aligns with Weight Watchers’ broader strategy to integrate medical treatments into its portfolio, offering members additional tools to address obesity and related health concerns.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 9, 2026

Author

GOAI